Melbourne-headquartered biopharmaceutical company Opthea Limited (ASX:OPT) has made a number of executive changes.
CEO, Dr Megan Baldwin, will transition to Founder and Chief Innovation Officer as part of the company’s strategy to advance its US and global presence and commercialisation strategy for sozinibercept (OPT-302).
The company has also appointments of US-based executives, Dr Frederic Guerard as Chief Executive Officer and Peter Lang as Chief Financial Officer.
Dr Guerard and Mr Lang are two well-respected healthcare executives with a record of building and growing organisations, guiding R&D pipelines, leading commercial operations, and managing finances while providing strategic direction and successfully steering companies through critical corporate, clinical and commercial growth inflection points.
“On behalf of the Board, I am pleased to welcome Fred Guerard and Peter Lang to Opthea’s leadership team. Both come to Opthea with impressive credentials to position Opthea for future growth and success,” said Dr Jeremy Levin, Chairman of Opthea’s Board of Directors. “We are also excited to create a new and essential role for Megan to continue to enhance the opportunity for sozinibercept and Opthea’s pipeline of next generation therapeutics for retinal diseases. Megan has dedicated much of her career to making Opthea what it is today and continues to be a critical member of the leadership team and Board of Directors.”
